Invent Medic Sweden (IMS) Q2 2026 earnings summary

Executive summary

• Achieved increased sales and significantly improved results in Q2 2026, with June marking the second profitable month of the year.

• Strategic shift and commercial focus are delivering results, with ongoing improvements in profitability and stability.

• Strengthened financial position through a successful rights issue, raising approximately 5.6 MSEK before costs.

Financial highlights

• Q2 2026 net revenue: 1,926 KSEK (up from 1,829 KSEK in Q2 2025).

• Q2 2026 result before tax: -818 KSEK (improved from -1,539 KSEK in Q2 2025).

• H1 2026 net revenue: 3,986 KSEK (up from 3,830 KSEK in H1 2025).

• H1 2026 result before tax: -1,649 KSEK (improved from -2,939 KSEK in H1 2025).

• Earnings per share for H1 2026: -0.01 SEK (improved from -0.03 SEK in H1 2025).

Outlook and guidance

• Focus remains on commercial development, internationalization, and consistent execution of strategy.

• Key priority is finding a distributor for Efemia in Sweden to enable further growth domestically and internationally.